132 related articles for article (PubMed ID: 15536331)
1. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases.
Nakanishi Y; Akimoto S; Sato Y; Kanai Y; Sakamoto M; Hirohashi S
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):323-8. PubMed ID: 15536331
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites.
Mitselou A; Batistatou A; Nakanishi Y; Hirohashi S; Vougiouklakis T; Charalabopoulos K
Histol Histopathol; 2010 Oct; 25(10):1257-67. PubMed ID: 20712010
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of dysadherin expression in advanced colorectal carcinoma.
Aoki S; Shimamura T; Shibata T; Nakanishi Y; Moriya Y; Sato Y; Kitajima M; Sakamoto M; Hirohashi S
Br J Cancer; 2003 Mar; 88(5):726-32. PubMed ID: 12618882
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma.
Shimada Y; Hashimoto Y; Kan T; Kawamura J; Okumura T; Soma T; Kondo K; Teratani N; Watanabe G; Ino Y; Sakamoto M; Hirohashi S; Imamura M
Oncology; 2004; 67(1):73-80. PubMed ID: 15459499
[TBL] [Abstract][Full Text] [Related]
6. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression.
Shimamura T; Sakamoto M; Ino Y; Sato Y; Shimada K; Kosuge T; Sekihara H; Hirohashi S
J Clin Oncol; 2003 Feb; 21(4):659-67. PubMed ID: 12586803
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer.
Tamura M; Ohta Y; Tsunezuka Y; Matsumoto I; Kawakami K; Oda M; Watanabe G
J Thorac Cardiovasc Surg; 2005 Sep; 130(3):740-5. PubMed ID: 16153922
[TBL] [Abstract][Full Text] [Related]
8. Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.
Izumi T; Oda Y; Hasegawa T; Nakanishi Y; Kawai A; Sonobe H; Takahira T; Kobayashi C; Yamamoto H; Tamiya S; Hirohashi S; Iwamoto Y; Tsuneyoshi M
Am J Surg Pathol; 2007 Jan; 31(1):85-94. PubMed ID: 17197923
[TBL] [Abstract][Full Text] [Related]
9. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance.
Kyzas PA; Stefanou D; Batistatou A; Agnantis NJ; Nakanishi Y; Hirohashi S; Charalabopoulos K
Am J Surg Pathol; 2006 Feb; 30(2):185-93. PubMed ID: 16434892
[TBL] [Abstract][Full Text] [Related]
10. Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma.
Batistatou A; Charalabopoulos AK; Scopa CD; Nakanishi Y; Kappas A; Hirohashi S; Agnantis NJ; Charalabopoulos K
Virchows Arch; 2006 Jun; 448(6):763-7. PubMed ID: 16570180
[TBL] [Abstract][Full Text] [Related]
11. Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC.
Ono K; Uramoto H; Hanagiri T
Anticancer Res; 2010 Sep; 30(9):3273-8. PubMed ID: 20944097
[TBL] [Abstract][Full Text] [Related]
12. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.
Batistatou A; Peschos D; Tsanou H; Charalabopoulos A; Nakanishi Y; Hirohashi S; Agnantis NJ; Charalabopoulos K
Br J Cancer; 2007 May; 96(9):1404-8. PubMed ID: 17437014
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of dysadherin expression in gastric cancer patients.
Shimada Y; Yamasaki S; Hashimoto Y; Ito T; Kawamura J; Soma T; Ino Y; Nakanishi Y; Sakamoto M; Hirohashi S; Imamura M
Clin Cancer Res; 2004 Apr; 10(8):2818-23. PubMed ID: 15102690
[TBL] [Abstract][Full Text] [Related]
14. Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion.
Maehata Y; Hirahashi M; Aishima S; Kishimoto J; Hirohashi S; Yao T; Takashima H; Tsuneyoshi M; Oda Y
Hum Pathol; 2011 Apr; 42(4):558-67. PubMed ID: 21239043
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of dysadherin and E-cadherin expression in patients with head and neck cancer treated by radiation therapy.
Muramatsu H; Akimoto T; Maebayashi K; Kita M; Mitsuhashi N
Anticancer Res; 2008; 28(6B):3859-64. PubMed ID: 19192641
[TBL] [Abstract][Full Text] [Related]
16. Dysadherin expression in gastrointestinal stromal tumors (GISTs).
Liang JF; Zheng HX; Xiao H; Li N; Cheng CX; Wang HK
Pathol Res Pract; 2009; 205(7):445-50. PubMed ID: 19217217
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of dysadherin expression in cervical squamous cell carcinoma.
Wu D; Qiao Y; Kristensen GB; Li S; Troen G; Holm R; Nesland JM; Suo Z
Pathol Oncol Res; 2004; 10(4):212-8. PubMed ID: 15619642
[TBL] [Abstract][Full Text] [Related]
18. Dysadherin: a new player in cancer progression.
Nam JS; Hirohashi S; Wakefield LM
Cancer Lett; 2007 Oct; 255(2):161-9. PubMed ID: 17442482
[TBL] [Abstract][Full Text] [Related]
19. Involvement of dysadherin and E-cadherin in the development of testicular tumours.
Batistatou A; Scopa CD; Ravazoula P; Nakanishi Y; Peschos D; Agnantis NJ; Hirohashi S; Charalabopoulos KA
Br J Cancer; 2005 Dec; 93(12):1382-7. PubMed ID: 16333245
[TBL] [Abstract][Full Text] [Related]
20. Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion.
Tsuiji H; Takasaki S; Sakamoto M; Irimura T; Hirohashi S
Glycobiology; 2003 Jul; 13(7):521-7. PubMed ID: 12672699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
